Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors-Reference-Cited by-同舟云学术

Phase I Study of Docetaxel and Temsirolimus in Refractory Solid Tumors

Published:2021-07-26 Issue:9 Volume:44 Page:443-448
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Amin Manik,Gao Feng,Terrero Gretel,Picus Joel,Wang-Gillam Andrea,Suresh Rama,Ma Cynthia,Tan Benjamin,Baggstrom Maria,Naughton Michael J.,Trull Lauren,Belanger Stephanie,Fracasso Paula M.,Lockhart Albert Craig

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference35 articles.

1. BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma—a trial of the ECOG-ACRIN Cancer Research Group (E2804);Flaherty;J Clin Oncol,2015

2. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma;Hutson;J Clin Oncol,2014

3. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma;Motzer;J Clin Oncol,2014

4. Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines;Aissat;Cancer Chemother Pharmacol,2008

5. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel;Faried;Eur J Cancer,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Classification and Pathogenesis of Pancreatic Adenocarcinoma and Targeted Therapies: A Review;Frontiers in Bioscience-Landmark;2024-03-13

2. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review);Oncology Reports;2023-10-04

3. Discovery of novel hybrids of mTOR inhibitor and NO donor as potential anti-tumor therapeutics;Bioorganic & Medicinal Chemistry;2023-08

4. Targeted therapy;Medicines for Cancer;2023

5. Boosting the Immune Response—Combining Local and Immune Therapy for Prostate Cancer Treatment;Cells;2022-09-07